NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (107 reviews)

For research use only.

Catalog No.S2638

107 publications

Molecular Weight(MW): 413.49

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Size Price Stock Quantity

10mM (1mL in DMSO) USD 112 In stock

5mg USD 70 In stock

10mg USD 120 In stock

50mg USD 370 In stock

200mg USD 970 In stock

Bulk Size Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (832) 582-8158 [email protected]

Selleck's NU7441 (KU-57788) has been cited by 107 publications

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Targets

DNA-PK ^[1]
(Cell-free assay)

14 nM

In vitro
NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID

NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe4VHZxUUN3ME2wMlAzOTR|IN88US=> Mm[5V2FPT0WU

A172 NWrJeIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULHSlJrUUN3ME2wMlE2OzF4IN88US=> MlTtV2FPT0WU

NCI-H526 NXPZXZRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMki0NFch|ryP NV\FN2VZW0GQR1XS

HDLM-2 M2nXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrzcFA5UUN3ME2wMlMzOzR3IN88US=> M4LUOXNCVkeHUh?=

HuO-3N1 NX7mNIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDwTWM2OD1yLkS2OlM3KM7:TR?= MlHVV2FPT0WU

NCI-SNU-1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXI[4dKSzVyPUCuOlA6QTRizszN NXPmfmFtW0GQR1XS

SK-N-AS M{i3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP3TWM2OD1yLk[yNlE3KM7:TR?= NUTHcHl5W0GQR1XS

LoVo NVj2Vnd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zo[2lEPTB;MD64Olc1QSEQvF2= MoDiV2FPT0WU

LAMA-84 NXHNW4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX0TWM2OD1yLkm4PFM{KM7:TR?= M1TObXNCVkeHUh?=

CTB-1 M4XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfUWmRKSzVyPUGuNVE2PDZizszN MojZV2FPT0WU

KP-N-YS M2Hl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS4TGN5UUN3ME2xMlE1OjNzIN88US=> NWnOblJTW0GQR1XS

HH M{fQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQemlEPTB;MT6xPFA6OyEQvF2= MoXYV2FPT0WU

CHL-1 NGjGempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi4TIRCUUN3ME2xMlIyOzZ6IN88US=> M3fHRnNCVkeHUh?=

NB7 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jWUWlEPTB;MT6yOFc1PSEQvF2= NVLsNnB2W0GQR1XS

HL-60 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwM{ixPUDPxE1? NFzSRmJUSU6JRWK=

639-V MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;1dYFKSzVyPUGuOFQyOjhizszN MVnTRW5ITVJ?

NCI-H1793 NWnGZnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHrTWM2OD1zLkS1PFQh|ryP Mlr3V2FPT0WU

NEC8 NYnHcIYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorJTWM2OD1zLkW1N|Uh|ryP NWK2XJpQW0GQR1XS

PA-1 NVTXTYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXiTpRKSzVyPUGuOVgzQTRizszN MoP6V2FPT0WU

D-423MG NED2VJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLuSZBKSzVyPUGuOlk{PjFizszN M2DWT3NCVkeHUh?=

NCI-H292 NEnIOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD1zLke0NFE{KM7:TR?= NV;MNXFNW0GQR1XS

SK-MEL-1 NGHFbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\1UnBSUUN3ME2xMlc6PDd7IN88US=> M32ycnNCVkeHUh?=

LB2241-RCC M3;hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToTWM2OD1{LkG0NVQ3KM7:TR?= MkHkV2FPT0WU

SK-MEL-3 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS3TWM2OD1{LkG2OFkh|ryP MUPTRW5ITVJ?

MHH-PREB-1 NXyxUoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ITWM2OD1{LkG2OlA6KM7:TR?= NHi3[nNUSU6JRWK=

BFTC-905 NGrMbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lTWM2OD1{LkG2Olg4KM7:TR?= M{X6N3NCVkeHUh?=

Ramos-2G6-4C10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwMUm5NFkh|ryP M4LGenNCVkeHUh?=

G-361 NIj5SFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPYbZZKSzVyPUKuNlE3QCEQvF2= MoP3V2FPT0WU

MOLT-4 NUPyNldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Yco9UUUN3ME2yMlIyQDh6IN88US=> NF;hNYVUSU6JRWK=

DEL NHXKbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTWc5VKSzVyPUKuN|U2PjRizszN MmjHV2FPT0WU

MV-4-11 NFT0VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLCSmpKSzVyPUKuN|c{QSEQvF2= M1THSHNCVkeHUh?=

SK-NEP-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TjTWlEPTB;Mj6zPFc5OyEQvF2= NXjZcZgyW0GQR1XS

RS4-11 M1e3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfoTWM2OD1{LkW2NFI{KM7:TR?= MXXTRW5ITVJ?

HuH-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTpZ2pKSzVyPUKuOVY4ODJizszN MX3TRW5ITVJ?

A101D M3H5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLnV3lzUUN3ME2yMlYyOzN6IN88US=> MYDTRW5ITVJ?

KG-1 M37EcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG1d4RKSzVyPUKuOlc6OjRizszN MUDTRW5ITVJ?

KALS-1 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fkfWlEPTB;Mj62PVY{OyEQvF2= NXTzS2F5W0GQR1XS

VMRC-RCZ M1iyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjRVJVwUUN3ME2yMlc4OzJ6IN88US=> MUjTRW5ITVJ?

SK-UT-1 M3nOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPXTWM2OD1|LkG1N|Eh|ryP M3H5XXNCVkeHUh?=

SW962 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;0[m9KSzVyPUOuNlA{PTJizszN NYrJRnBpW0GQR1XS

DBTRG-05MG NHq3bXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\rXmlEPTB;Mz6yPFA5PSEQvF2= Mo[xV2FPT0WU

PANC-08-13 NWXsSWNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfweFF5UUN3ME2zMlQyOjd6IN88US=> M3;NRXNCVkeHUh?=

QIMR-WIL Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;1VZVKSzVyPUOuOFE{PDFizszN NH:3UmtUSU6JRWK=

SK-MEL-30 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnxT3ZKSzVyPUOuOFI2QThizszN NGTxXllUSU6JRWK=

697 NVLib|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zreGlEPTB;Mz60OFk6OyEQvF2= NIWxZ5NUSU6JRWK=

NY MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwNEWwNlIh|ryP NV\KbXRDW0GQR1XS

ES7 NH\BcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXeyXlloUUN3ME2zMlQ3PzJ7IN88US=> NImzU|JUSU6JRWK=

JVM-3 M2PjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNwNEiwO|ch|ryP NH;xXoJUSU6JRWK=

U031 NVfSXld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwNUmzOlgh|ryP M3v1SXNCVkeHUh?=

BHT-101 NGOwXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwNUm5PFUh|ryP MnjPV2FPT0WU

8305C NUfoVmt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTWRpRmUUN3ME2zMlYyPzN4IN88US=> MYXTRW5ITVJ?

MG-63 NYrZNYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;vTWM2OD1|Lk[yOlc3KM7:TR?= M4TGS3NCVkeHUh?=

NOS-1 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwNkWzNVIh|ryP Mn72V2FPT0WU

YH-13 M2\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD1|Lki3NVg6KM7:TR?= MlHzV2FPT0WU

LXF-289 NUnzRoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW3N5ZKSzVyPUOuPVExPDFizszN NVnhbIc{W0GQR1XS

GOTO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwOUG0PUDPxE1? M1rvfnNCVkeHUh?=

EKVX MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LJ[mlEPTB;ND6yNlUzPCEQvF2= NFnQZWpUSU6JRWK=

CAL-51 NYTGRVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaXo1KSzVyPUSuNlQ5PTRizszN MlO0V2FPT0WU

AN3-CA Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRwMkW4NVMh|ryP MXjTRW5ITVJ?

IA-LM MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYSXhFUUN3ME20MlI4QTN3IN88US=> NYXUNHJXW0GQR1XS

KU-19-19 M1:3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwM{K5NlEh|ryP M1nh[HNCVkeHUh?=

A704 NYjRWXdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTRwNEC4PFgh|ryP MkThV2FPT0WU

RH-18 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHiTWM2OD12LkS0PVU{KM7:TR?= MVHTRW5ITVJ?

IST-MEL1 NUHMR45rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4TWM2OD12LkW4NlY{KM7:TR?= MUjTRW5ITVJ?

LU-134-A MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZdGlEPTB;ND61PVY5PSEQvF2= NVvLdnFjW0GQR1XS

SF126 M{\CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fPNWlEPTB;ND62NFcyPSEQvF2= NEfnWnFUSU6JRWK=

EFO-27 NXPSWo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGcWlEPTB;ND62OlUzPSEQvF2= MXnTRW5ITVJ?

SN12C NXTGTmJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\yTWM2OD12LkexPFk5KM7:TR?= NHLJNFZUSU6JRWK=

L-363 NUf4ZpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwN{exNVYh|ryP M1nGeXNCVkeHUh?=

MEL-HO M1jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPUfnZIUUN3ME20Mlc4QTh7IN88US=> NYGySmNjW0GQR1XS

TYK-nu MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwOECxNlgh|ryP NXzKO283W0GQR1XS

MDA-MB-415 NVrnboJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEewOGhKSzVyPUWuNFA{OTRizszN MkmwV2FPT0WU

HCC70 NWLJfHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TX[2lEPTB;NT6wN|k{QSEQvF2= NITiNGVUSU6JRWK=

IGROV-1 NUf5UnE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTVwMkWyPVIh|ryP MkjKV2FPT0WU

NCI-H1355 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1OXJ1UUN3ME21MlI6PiEQvF2= MlL1V2FPT0WU

23132-87 NFKxeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rkd2lEPTB;NT6zNlAzPCEQvF2= NFrlc3VUSU6JRWK=

NB69 NFHa[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEeyUppKSzVyPUWuN|I1OiEQvF2= MnH1V2FPT0WU

HSC-2 NGHKPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHETWM2OD13LkSxO|c{KM7:TR?= MWTTRW5ITVJ?

KYSE-410 NET4VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwNEe2N|Yh|ryP M{LWXXNCVkeHUh?=

GCIY M1vsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MfY56UUN3ME21MlUyOzd6IN88US=> MWTTRW5ITVJ?

A427 NEjNbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEniXmdKSzVyPUWuOVM3PjFizszN M1jyZXNCVkeHUh?=

ChaGo-K-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjWOVVSUUN3ME21MlU3PTl7IN88US=> MofoV2FPT0WU

PFSK-1 M{Hr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKTWM2OD13Lk[yNVk1KM7:TR?= NF;FdIJUSU6JRWK=

MLMA M1;ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnkWHVKSzVyPUWuPFM3ODZizszN M4OyTHNCVkeHUh?=

RVH-421 NVXGV3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LpeWlEPTB;Nj6wO|M{QCEQvF2= MX\TRW5ITVJ?

LB1047-RCC NYHjUW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zFZWlEPTB;Nj6xO|UzOiEQvF2= MoPyV2FPT0WU

MHH-NB-11 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnWN|FKSzVyPU[uN|I4OjFizszN M4XITHNCVkeHUh?=

J-RT3-T3-5 NHza[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m0UmlEPTB;Nj62N|I6OSEQvF2= MVXTRW5ITVJ?

UM-UC-3 M4\4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1eWtuUUN3ME22MlY1OzN2IN88US=> Mm[wV2FPT0WU

IST-SL1 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCeXIxUUN3ME22MlY6OzZ7IN88US=> MV;TRW5ITVJ?

NB14 M3i1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7BW5dKSzVyPU[uO|k4PjFizszN MYDTRW5ITVJ?

NBsusSR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsNGlEPTB;Nj64NlUxOiEQvF2= M2TkZnNCVkeHUh?=

D-263MG M{e1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PGOmlEPTB;Nj65NVA3QCEQvF2= M3LvTnNCVkeHUh?=

NCI-H2347 NVT2XYVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[3RmlEPTB;Nj65N|IyOyEQvF2= M1fzbHNCVkeHUh?=

ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPPVGJKSzVyPU[uPVc2QDhizszN NWXJcYVxW0GQR1XS

786-0 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq2TWM2OD15LkC5O|g3KM7:TR?= NGXzZ3dUSU6JRWK=

EPLC-272H NFTl[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfJTodKSzVyPUeuNVYzPDZizszN MVLTRW5ITVJ?

CAPAN-1 M2X0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwMkSzOVkh|ryP M{fxeHNCVkeHUh?=

NCI-H82 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\oOVFKSzVyPUeuNlY3PTlizszN NXPJe4kzW0GQR1XS

G-402 M3j3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH6VXhKSzVyPUeuN|AxPTFizszN MWrTRW5ITVJ?

SW982 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7RTHRKSzVyPUeuN|AzODNizszN MWjTRW5ITVJ?

OVCAR-4 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO0fnpKSzVyPUeuN|E{OjhizszN NFK2UZNUSU6JRWK=

KARPAS-299 NFO4bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD15LkOyOlIzKM7:TR?= NULtOYJPW0GQR1XS

MIA-PaCa-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTdwM{[4NlMh|ryP NFHSS4NUSU6JRWK=

AU565 NFPTbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnrO2VqUUN3ME23MlU6QDN|IN88US=> NETzZpFUSU6JRWK=

GAMG Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwNkSxN|Eh|ryP NXTDenVWW0GQR1XS

HuO9 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1njZWlEPTB;Nz63NVc1OyEQvF2= NUPRd25iW0GQR1XS

ACN NF\tVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwdYx1UUN3ME23Mlc1OzNizszN M3u3UXNCVkeHUh?=

RO82-W-1 NGfaT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7yeGZ6UUN3ME23Mlc1PTN|IN88US=> NVjkSW1bW0GQR1XS

NKM-1 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLteFFjUUN3ME23Mlc1QTV3IN88US=> MXvTRW5ITVJ?

CAL-12T NHzUUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdwOUSzOVIh|ryP NYLnc5ByW0GQR1XS

FADU MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRThwMEO2OVQh|ryP MX\TRW5ITVJ?

NCI-H28 NYrnR3ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHzTWM2OD16LkG2PVYzKM7:TR?= NV3wOZlWW0GQR1XS

LCLC-97TM1 NXztPIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDtTWM2OD16LkKxNVIzKM7:TR?= NF7afo1USU6JRWK=

CHP-134 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKwRVk4UUN3ME24MlI1OTh3IN88US=> MofXV2FPT0WU

HT-1080 M4nkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jMdGlEPTB;OD6yOVA6OyEQvF2= MkW3V2FPT0WU

PC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHHPXNXUUN3ME24MlI4Ozl{IN88US=> M2TGPXNCVkeHUh?=

SNU-449 NEn1XlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;UTWM2OD16LkK3PVMh|ryP MUHTRW5ITVJ?

VA-ES-BJ M{jUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKTWlEPTB;OD6zOFY5PiEQvF2= Mnf6V2FPT0WU

HT NI\UT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq1TWM2OD16LkO2OFkh|ryP NXni[VY5W0GQR1XS

HOS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXOd5JKSzVyPUiuN|c2QDlizszN MVfTRW5ITVJ?

KNS-62 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlraTWM2OD16LkO3O|YzKM7:TR?= NYL2VHFuW0GQR1XS

OAW-42 NF63OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzSU3JMUUN3ME24Mlk2QTZ2IN88US=> NUDxd5NrW0GQR1XS

A549 NUXaNo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTlwMEm2NVIh|ryP NV\BN2Z{W0GQR1XS

CAKI-1 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TSeWlEPTB;OT6xOlYyKM7:TR?= MoLyV2FPT0WU

HCC1937 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\sXndQUUN3ME25MlY6QDZ3IN88US=> MmHCV2FPT0WU

GI-ME-N M4\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHJTWM2OD17LkewNVM4KM7:TR?= NHmxT|BUSU6JRWK=

DU-4475 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPvWXVKSzVyPUmuPVY6OzlizszN NXnUSVhDW0GQR1XS

EM-2 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXzXoZKSzVyPUGwMlI1OjZizszN M4r4THNCVkeHUh?=

NCI-H1755 NWjRXnRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnHTWM2OD1zMD6yOFI5KM7:TR?= MXPTRW5ITVJ?

NCI-H1437 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFyLkW3NlUh|ryP M{DkOXNCVkeHUh?=

VM-CUB-1 NGS1VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILWe41KSzVyPUGwMlYyPjRizszN NFe1bXFUSU6JRWK=

A2058 NWPjeIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1zMD62OFA1KM7:TR?= NWHPbo9qW0GQR1XS

BPH-1 M4fpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzSOnB6UUN3ME2xNE44OTR3IN88US=> Mm\tV2FPT0WU

NB5 NYj3[mRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFyLke1OVkh|ryP NUS4SY0zW0GQR1XS

G-401 NEjOdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxe41lUUN3ME2xNE44PjJ4IN88US=> NV;pS3Y5W0GQR1XS

CAL-72 M3Xa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nU[mlEPTB;MUCuPFA6PCEQvF2= MnSwV2FPT0WU

SK-MEL-28 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13sW2lEPTB;MUCuPFIxOiEQvF2= NFrVPHhUSU6JRWK=

C32 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXWTWM2OD1zMD64N|Q4KM7:TR?= NV\1NmJ4W0GQR1XS

NCI-H1155 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP5WWtKSzVyPUGwMlg{PzZizszN M1q1NXNCVkeHUh?=

BB49-HNC NFm1fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFyLki1PFYh|ryP MWfTRW5ITVJ?

GMS-10 MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyLki5O|Eh|ryP NVPYdWVOW0GQR1XS

K5 M1vIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDLTWM2OD1zMD65NFcyKM7:TR?= M1jaVXNCVkeHUh?=

OS-RC-2 M2\PVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFzLkC1OVkh|ryP MW\TRW5ITVJ?

HTC-C3 NV7HOpRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfQTWM2OD1zMT6wO|E1KM7:TR?= M1rBW3NCVkeHUh?=

LB996-RCC NFP0OlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G5WmlEPTB;MUGuNFczOyEQvF2= Mm\FV2FPT0WU

NCI-H1563 M2XacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7wPJRKSzVyPUGxMlExOTFizszN NUmxWpZ7W0GQR1XS

CAL-54 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDIfm05UUN3ME2xNU41QDFzIN88US=> MWXTRW5ITVJ?

WM-115 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTOYZsUUN3ME2xNU43QDJ2IN88US=> MoDDV2FPT0WU

COLO-684 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LUfGlEPTB;MUGuO|I3PyEQvF2= NXSxT|c5W0GQR1XS

HOP-62 M1;Ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjWS4VKSzVyPUGxMlc2ODhizszN NF\VTG5USU6JRWK=

NCI-H650 NYDmXFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;IXlRKSzVyPUGxMlg6PjFizszN MX7TRW5ITVJ?

TE-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P0UGlEPTB;MUGuPVMyPSEQvF2= NGXlW5dUSU6JRWK=

COLO-679 NX;2b2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFzLkm0OkDPxE1? MlPkV2FPT0WU

FTC-133 M2fLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVemlEPTB;MUKuNFA4PiEQvF2= M3[yNnNCVkeHUh?=

D-283MED M1z5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D2SGlEPTB;MUKuNFU3QSEQvF2= Mn3xV2FPT0WU

SK-PN-DW NF\ke2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xTWM2OD1zMj6xPVAzKM7:TR?= NV3SSoZOW0GQR1XS

BALL-1 NYPJVYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjETWM2OD1zMj6yOlYzKM7:TR?= MUPTRW5ITVJ?

GT3TKB MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW1TWM2OD1zMj6zNFc1KM7:TR?= M4PFZ3NCVkeHUh?=

HOP-92 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nWPWlEPTB;MUKuOVI{OyEQvF2= MXHTRW5ITVJ?

M14 NUXBT5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTvTWM2OD1zMz6wN|M2KM7:TR?= MXzTRW5ITVJ?

SKG-IIIa M2W3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fMOmlEPTB;MUOuNFU2PCEQvF2= MkXUV2FPT0WU

Becker M{K2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi3enBKSzVyPUGzMlA2QCEQvF2= MYDTRW5ITVJ?

ES5 NYToUXBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTVdo5CUUN3ME2xN{4yOzV4IN88US=> M2H3W3NCVkeHUh?=

NCI-H2030 NUfQVoxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f6O2lEPTB;MUOuNlA3OiEQvF2= NVn6fVlvW0GQR1XS

SNU-423 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SeJZFUUN3ME2xN{4{QDFizszN MnnNV2FPT0WU

CP50-MEL-B M4DZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonWTWM2OD1zMz62NlMzKM7:TR?= M2XGUHNCVkeHUh?=

NCI-H1092 NHH6bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHPTWM2OD1zMz63OFc2KM7:TR?= Mmm5V2FPT0WU

8-MG-BA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfoTWM2OD1zMz63OVE{KM7:TR?= M4roXHNCVkeHUh?=

CAL-27 NFzTVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f6RmlEPTB;MUSuNFczPyEQvF2= NHzGUpZUSU6JRWK=

AGS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2emlEPTB;MUSuNVMyQSEQvF2= MX3TRW5ITVJ?

MZ2-MEL M1;0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2LkG0PFgh|ryP M4PZPXNCVkeHUh?=

BFTC-909 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\kTZdVUUN3ME2xOE42ODV3IN88US=> MUHTRW5ITVJ?

D-566MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF2Lke3NFYh|ryP NV3jS4RoW0GQR1XS

MZ7-mel MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjJZ4ljUUN3ME2xOU4yODZ5IN88US=> MkPEV2FPT0WU

TE-5 NUDTeHM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjuTGh{UUN3ME2xOU4zOzN|IN88US=> MnzuV2FPT0WU

647-V M1;SfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjYUoRKSzVyPUG1MlI4ODVizszN NILuU2pUSU6JRWK=

DMS-114 M3HzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr6b|QyUUN3ME2xOU4{OjlzIN88US=> M33B[3NCVkeHUh?=

ME-180 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37weGlEPTB;MUWuOFc5OyEQvF2= NUXDOGhXW0GQR1XS

MS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF3LkW2NlMh|ryP MmnZV2FPT0WU

NUGC-3 M4PBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF3Lk[yOFUh|ryP NHXIOXJUSU6JRWK=

GB-1 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLiNnZ2UUN3ME2xOU43PDN5IN88US=> MnnvV2FPT0WU

LOXIMVI MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HyRmlEPTB;MUWuPFkyQSEQvF2= NELielhUSU6JRWK=

NCI-H1304 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXNUVRKSzVyPUG1Mlg6OjhizszN M{f1bXNCVkeHUh?=

KURAMOCHI NH\iVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;0XFVKSzVyPUG1Mlk4OSEQvF2= M2TDdXNCVkeHUh?=

SW1783 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTiOppKSzVyPUG2MlA6QTNizszN NUnPOI9rW0GQR1XS

EGI-1 M3PYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH1TWM2OD1zNj61N|Y2KM7:TR?= MlzaV2FPT0WU

KGN NFS4bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPVWGVYUUN3ME2xOk42PTh4IN88US=> NV20PWVDW0GQR1XS

PANC-03-27 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF4Lke2OlIh|ryP M{[0eXNCVkeHUh?=

RH-1 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\tenprUUN3ME2xOk45OjVizszN NFHNNppUSU6JRWK=

HT-1376 M3XOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF4Lki0OFYh|ryP NXHGZYM5W0GQR1XS

ZR-75-30 M3vTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4UIhKSzVyPUG2Mlk{PjFizszN NXHZUJJvW0GQR1XS

TI-73 M4LIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TCXWlEPTB;MU[uPVQxQCEQvF2= MUPTRW5ITVJ?

TK10 M1L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF5LkCwO|kh|ryP MXLTRW5ITVJ?

SW684 NUKzXpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzhXGtKSzVyPUG3MlAyPTRizszN NUPxeI17W0GQR1XS

RPMI-8866 M3LFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF5LkC2PVkh|ryP NUfh[ohJW0GQR1XS

LNCaP-Clone-FGC NWHENWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF5LkWyNFEh|ryP NIO4R2JUSU6JRWK=

NCI-H2291 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfnNnFKSzVyPUG4MlQ{PDVizszN NFjhXmFUSU6JRWK=

T47D NIrMSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGyVnZKSzVyPUG4MlQ5QCEQvF2= NV\QSnI1W0GQR1XS

A204 M3faTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnYTWM2OD1zOD61OFUzKM7:TR?= MkTEV2FPT0WU

HT-144 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvZfpdKSzVyPUG4Mlc1OjdizszN NVv3OHlPW0GQR1XS

MDA-MB-361 M3O5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHKbWtKSzVyPUG5MlA4OTRizszN NXXwUVFRW0GQR1XS

HCC1806 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXqTWM2OD1zOT6xOVkyKM7:TR?= NUXvXZNLW0GQR1XS

NCI-H596 M4rCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTFTWM2OD1zOT62N|kyKM7:TR?= NFG5ZXpUSU6JRWK=

K-562 M2LLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTUcJBnUUN3ME2xPU45QTJ4IN88US=> MV7TRW5ITVJ?

D-336MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2SHhKSzVyPUG5Mlk{OjJizszN NEPyZphUSU6JRWK=

SK-MEL-2 M{P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnmOol3UUN3ME2yNE4yPTV7IN88US=> NVT3SGlFW0GQR1XS

HEC-1 NUXYOmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hv[WlEPTB;MkCuOFk4QCEQvF2= MVjTRW5ITVJ?

EW-13 NF\WZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7iTWM2OD1{MD61OFQ{KM7:TR?= MWrTRW5ITVJ?

Hs-578-T NUTQNYpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzMXJZKSzVyPUKwMlU2QDNizszN MmnBV2FPT0WU

SJSA-1 M{K0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq0TWM2OD1{MD61Olg5KM7:TR?= NHHFOGJUSU6JRWK=

RCC10RGB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfBTWM2OD1{MD62O|E6KM7:TR?= M3\zc3NCVkeHUh?=

LAN-6 M4S3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHtTWM2OD1{MT6wN|k3KM7:TR?= NEL1dJFUSU6JRWK=

NCI-H1048 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTtfIlKSzVyPUKxMlIzPThizszN M362TXNCVkeHUh?=

CW-2 NVy3RpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLlRoNKSzVyPUKxMlI4ODVizszN MnPGV2FPT0WU

HCC2157 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJzLkO2JO69VQ>? MWrTRW5ITVJ?

EW-22 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJzLkO3OkDPxE1? M2LWXnNCVkeHUh?=

A253 NFPWSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHsVnlKSzVyPUKxMlQ1QDFizszN MnXqV2FPT0WU

BE-13 M1nwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i1WGlEPTB;MkGuOlEyOyEQvF2= MVLTRW5ITVJ?

KINGS-1 NFnkXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG4dIt[UUN3ME2yNU43OzF4IN88US=> NYPZOXBMW0GQR1XS

ETK-1 NXTlOmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LscGlEPTB;MkGuPFE2OiEQvF2= NYjkVFh5W0GQR1XS

NCI-H2452 M3nKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjUVXZ2UUN3ME2yNU45PjR5IN88US=> M{XaTXNCVkeHUh?=

HPAF-II NYnYbpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2V5BuUUN3ME2yNU45QTJ|IN88US=> NYTZOVRoW0GQR1XS

D-542MG NUXTcpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJzLkmwOlkh|ryP NGWydHlUSU6JRWK=

NCI-H630 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ{LkCyPVYh|ryP NHPMfldUSU6JRWK=

TGBC11TKB M1\vNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL2TWM2OD1{Mj6wOFkh|ryP NIHsZVdUSU6JRWK=

BCPAP NIH1PFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJ{Lk[xNUDPxE1? NYnuV3pvW0GQR1XS

HLE MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ{Lk[5O{DPxE1? MUjTRW5ITVJ?

NCI-H727 NI[ye2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vZXWlEPTB;MkKuO|M2KM7:TR?= MWTTRW5ITVJ?

RD NYXlSWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OzcGlEPTB;MkKuO|UyQCEQvF2= MYjTRW5ITVJ?

NCI-H522 NH3lbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:xPVBKSzVyPUKyMlg1OzFizszN Ml7RV2FPT0WU

CGTH-W-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH23bmRKSzVyPUKzMlA3PDFizszN NGfi[3FUSU6JRWK=

SK-LU-1 NEH3b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ|LkS2PFMh|ryP MVjTRW5ITVJ?

BB65-RCC NYXCV4ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ|Lke4OlMh|ryP M4XHPXNCVkeHUh?=

HSC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ofGlEPTB;MkOuPFUzPyEQvF2= MWjTRW5ITVJ?

SK-MES-1 M{nteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ2LkCxOlEh|ryP MWDTRW5ITVJ?

DB M2rEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uzUmlEPTB;MkSuNVAzQCEQvF2= MWLTRW5ITVJ?

HO-1-N-1 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ2LkOwPVMh|ryP M3zr[XNCVkeHUh?=

MKN1 M2WxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ2Lk[4JO69VQ>? M4P6e3NCVkeHUh?=

MN-60 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ2Lki1NVkh|ryP NF7WdYxUSU6JRWK=

8505C MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\DSZBqUUN3ME2yOU4yQDR3IN88US=> Moi0V2FPT0WU

COLO-320-HSR MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ3LkKyNFgh|ryP M2rqOHNCVkeHUh?=

BB30-HNC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLhfZduUUN3ME2yOU4zPDh|IN88US=> Mn;nV2FPT0WU

KM12 NHnxb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ3LkW4NFch|ryP M4\yZXNCVkeHUh?=

NB13 NFHlSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ3LkW4PVgh|ryP MXjTRW5ITVJ?

HCC2998 M2nHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfKVXFKSzVyPUK2MlAzQDNizszN Mnz1V2FPT0WU

U-118-MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ4LkC4NFgh|ryP MUfTRW5ITVJ?

NB10 NGrD[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13pXGlEPTB;Mk[uNlM1KM7:TR?= NVvqeYpOW0GQR1XS

SK-LMS-1 NF32SnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTKUYp7UUN3ME2yO{4xPzB2IN88US=> NUTYPIp2W0GQR1XS

SW1573 M1;Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHVXm5KSzVyPUK3MlEyKM7:TR?= Ml6yV2FPT0WU

LB373-MEL-D M4XlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfZbGJDUUN3ME2yO{4yOjl2IN88US=> MkPwV2FPT0WU

DK-MG M2fMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofJTWM2OD1{Nz6xPFE4KM7:TR?= M4HNVXNCVkeHUh?=

RMG-I MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fTXWlEPTB;MkeuNlAzQSEQvF2= MlvqV2FPT0WU

SW1088 NXXOfXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fwO2lEPTB;MkeuOVA1OiEQvF2= MX3TRW5ITVJ?

SK-OV-3 NFuzfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ5Lke1PVMh|ryP NXjoXVZIW0GQR1XS

KP-N-YN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrHTXBKSzVyPUK3MlgxPDNizszN MVPTRW5ITVJ?

RPMI-7951 M1zHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXYc2lMUUN3ME2yPE4zPDV4IN88US=> M3PnXnNCVkeHUh?=

CaR-1 M1K4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ6LkW1PFIh|ryP MUnTRW5ITVJ?

MKN7 M4T4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LwUmlEPTB;MkiuOVk3PCEQvF2= MXTTRW5ITVJ?

CHP-212 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ6Lke0NFEh|ryP MV3TRW5ITVJ?

KYSE-450 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnpSJBsUUN3ME2yPE45ODlzIN88US=> MVfTRW5ITVJ?

RXF393 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ7LkK5NFYh|ryP NXWwS4oyW0GQR1XS

P30-OHK NFe0UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHDO3BKSzVyPUK5MlMxPDhizszN NYrhOpRtW0GQR1XS

Ca9-22 NHvSNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ7LkSyPVkh|ryP NHn3cZZUSU6JRWK=

RT-112 NFroUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\XfZZKSzVyPUK5MlQ3OTFizszN MXHTRW5ITVJ?

ES1 NIj3[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPSTWM2OD1{OT64OVQ1KM7:TR?= NXHWeJE3W0GQR1XS

HCE-4 M1XTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn70TWM2OD1{OT64O|g3KM7:TR?= M{L3XnNCVkeHUh?=

AM-38 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNyLkC2NFYh|ryP Mle4V2FPT0WU

AsPC-1 NX7lbI5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNyLkiwOVMh|ryP NYTVWYxyW0GQR1XS

TE-9 M{PYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTxVmJKSzVyPUOwMlg4OzdizszN M1vkXHNCVkeHUh?=

HuP-T4 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP6TWM2OD1|MD65OlM5KM7:TR?= M4nxXXNCVkeHUh?=

LB2518-MEL MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\mXGlEPTB;M{GuNFc1PCEQvF2= NV24SHFoW0GQR1XS

NCI-H1703 M1;k[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n6V2lEPTB;M{GuNFkxPSEQvF2= NIXOTXdUSU6JRWK=

NCI-H2228 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNzLkS2OVEh|ryP NWfkW5oxW0GQR1XS

SCC-4 NWi4bYN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUKzVotUUUN3ME2zNU46OThzIN88US=> MWPTRW5ITVJ?

KNS-81-FD MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN{LkCxNlgh|ryP NWjOUYhjW0GQR1XS

NTERA-S-cl-D1 NVvHPXh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:3U4RkUUN3ME2zNk4xPzN7IN88US=> NHzqRo1USU6JRWK=

Daoy NEficGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWy[ld6UUN3ME2zNk4xQDN6IN88US=> MXTTRW5ITVJ?

ES4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1R2lEPTB;M{KuN|kzOiEQvF2= MXLTRW5ITVJ?

MHH-ES-1 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED2dJJKSzVyPUOyMlQ5PzJizszN MV3TRW5ITVJ?

C-33-A NInM[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2[5ZXUUN3ME2zNk44PzJ6IN88US=> M{DoOHNCVkeHUh?=

BHY NUHofY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rremlEPTB;M{KuPVQ6PSEQvF2= MmLNV2FPT0WU

Detroit562 NWjoW5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN|Lk[2OVch|ryP NF7CWlNUSU6JRWK=

EW-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHQWlUzUUN3ME2zN{46OzJ{IN88US=> M4X0OHNCVkeHUh?=

NCI-H1395 NHH6UIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PFNGlEPTB;M{SuNFc6QSEQvF2= M3Hnb3NCVkeHUh?=

KM-H2 M3faTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\NfXNKSzVyPUO2MlQ4PDNizszN NY\K[HA4W0GQR1XS

NCI-H520 NX3kcpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\zTWM2OD1|Nj63OVQyKM7:TR?= MYnTRW5ITVJ?

D-392MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjyPG1KSzVyPUO3MlM{PDRizszN M1jLRnNCVkeHUh?=

NOMO-1 NX7vflBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fvc2lEPTB;M{euPFA5QSEQvF2= MWrTRW5ITVJ?

TE-6 NYTsTGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vSZWlEPTB;M{iuNVI1KM7:TR?= M4jYNnNCVkeHUh?=

HT-3 NYLjOmJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLrXVJRUUN3ME2zPE41PDN4IN88US=> M4fIcnNCVkeHUh?=

RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTBUlZoUUN3ME2zPE46PTF7IN88US=> Mme4V2FPT0WU

U251 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7XZ4xKSzVyPUO5MlAyOjRizszN MnrjV2FPT0WU

GCT MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4riPGlEPTB;M{muNVg2OiEQvF2= NEnI[VVUSU6JRWK=

A431 NIDWd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN7LkG4PVQh|ryP NUXHWIl[W0GQR1XS

TE-12 M3LncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP6TWM2OD1|OT6yOFQ5KM7:TR?= MlK0V2FPT0WU

HMV-II NWjINXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3TWM2OD1|OT61NFQ4KM7:TR?= MYHTRW5ITVJ?

IST-MES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZVoVKSzVyPUSwMlE2ODJizszN MonFV2FPT0WU

SW13 NV65N|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRyLkWxPUDPxE1? NIrNOJpUSU6JRWK=

SF295 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDvXIxKUUN3ME20NE45ODZ4IN88US=> NGC0fodUSU6JRWK=

MDA-MB-157 M3TXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TMS2lEPTB;NECuPVQ3OiEQvF2= M1nEe3NCVkeHUh?=

TE-1 NYfkdZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPEcpFKSzVyPUSxMlg4OTRizszN NVzWNGk2W0GQR1XS

HuCCT1 NUDyVVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjjTWM2OD12Mj61Nlg6KM7:TR?= MV\TRW5ITVJ?

KYSE-510 NGfUboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DBNmlEPTB;NEOuNVc2PCEQvF2= M3v2XXNCVkeHUh?=

NCI-H358 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKzTWM2OD12ND6wN|A1KM7:TR?= NWLqb4RyW0GQR1XS

SW900 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR2LkC3OVgh|ryP NEPvOpVUSU6JRWK=

CAS-1 NULjWnhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfkS|hKSzVyPUS0MlA6QTFizszN NHTYXIVUSU6JRWK=

TE-8 NXrjeJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrZTWM2OD12ND61OlU5KM7:TR?= MlLhV2FPT0WU

P12-ICHIKAWA NELifIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOXGlEPTB;NESuOlEyOiEQvF2= NYTGVpBPW0GQR1XS

YKG-1 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jJfmlEPTB;NESuO|gyKM7:TR?= M4XxTXNCVkeHUh?=

SNU-C2B NU\kNJJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR2Lke5NFMh|ryP MUDTRW5ITVJ?

LCLC-103H M{j5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:zTWM2OD12ND64O|A{KM7:TR?= MWjTRW5ITVJ?

U-87-MG NHvqS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR3LkGwNlIh|ryP NXvFRXAzW0GQR1XS

HAL-01 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR3LkGzO|kh|ryP M4DST3NCVkeHUh?=

OVCAR-8 NGi2[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNd2lEPTB;NEWuN|U3PCEQvF2= NEXySYxUSU6JRWK=

KYSE-150 NV\TeFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPoUnVKSzVyPUS3MlExPTJizszN NFzYNHJUSU6JRWK=

OE33 NEnkSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrPR|lKSzVyPUS3MlE1OjlizszN M2C1SXNCVkeHUh?=

CAL-62 NYHneoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR5LkSwOlgh|ryP NYnH[|BPW0GQR1XS

TCCSUP M1;WVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD12Nz62NlY1KM7:TR?= NWKySmQxW0GQR1XS

H4 NGnidpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXnRm5KSzVyPUS3MlY3OjFizszN M1XjbnNCVkeHUh?=

CP66-MEL MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPoTWM2OD12OD6wO|A1KM7:TR?= NYHBUopWW0GQR1XS

SNB75 M2frN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR6LkG4O|Qh|ryP NIrXNm1USU6JRWK=

Mo-T MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR6LkK3PUDPxE1? MnXaV2FPT0WU

BT-549 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR6LkO3Nlkh|ryP MmL0V2FPT0WU

IGR-1 NVHBc5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTJTWM2OD12OD62OlQ2KM7:TR?= NH7tVZpUSU6JRWK=

NCI-H1299 NHnpWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR6LkeyOFgh|ryP MVPTRW5ITVJ?

ALL-PO NV3KeIQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHOTWM2OD12OT65NlY5KM7:TR?= MYLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods Test Index PMID

Western blot
p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51;

PubMed: 29344644      Oncol Rep

SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR.

p-mTOR(Ser2448) / mTOR / p-S6K(Thr389);

PubMed: 25714019      Oncotarget

Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.

29344644 25714019

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:
^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells

Concentrations: 0.5 μM or 1 μM

Incubation Time: 17 hours

Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:
^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts

Dosages: 10 mg/kg

Administration: Intraperitoneally administrated
(Only for Reference)

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

[3] Tavecchio M, et al. Cancer Chemother Pharmacol, 2012, 69(1), 155-164.

[4] Cruet-Hennequart S, et al. DNA Repair (Amst), 2006, 5(4), 491-504.

[5] Willmore E, et al. Clin Cancer Res, 2008, 14(12), 3984-3992.

[6] Elliott SL, et al. Br J Haematol, 2011, 152(1), 61-71.

[7] Robert F, et al. Genome Med. 2015, 7:93.

- Collapse

Solubility (25°C)

In vitro DMSO 4 mg/mL warmed (9.67 mM)

Water Insoluble

Ethanol Insoluble

In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight 413.49

Formula
C₂₅H₁₉NO₃S

CAS No. 503468-95-9

Storage 3 years-20°C powder
2 years-80°C in solvent

Synonyms N/A

Smiles O=C1C=C(OC2=C1C=CC=C2C3=CC=CC4=C3SC5=C4C=CC=C5)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O %DMSO+ %

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Method for preparing in vivo formulation：Take μL DMSO master liquid,next add μL Corn oil，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
           2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

=

×

×

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

C1

V1

C2

V2

×

=

×

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions

Concertration (start):

Dilution-folds:

Computed Result

C1=C0/X C1: LOG(C1):

C2=C1/X C2: LOG(C2):

C3=C2/X C3: LOG(C3):

C4=C3/X C4: LOG(C4):

C5=C4/X C5: LOG(C5):

C6=C5/X C6: LOG(C6):

C7=C6/X C7: LOG(C7):

C8=C7/X C8: LOG(C8):

Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

= × ×

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name:

* E-Mail:

Phone:

* Comments:

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?

Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.

Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?

Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.

Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.

Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

NU7026

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Selleck's NU7441 (KU-57788) has been cited by 107 publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

In vivo Formulation Calculator (Clear solution)

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	O=C1C=C(OC2=C1C=CC=C2C3=CC=CC4=C3SC5=C4C=CC=C5)N6CCOCC6

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Selleck's NU7441 (KU-57788) has been cited by 107 publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

In vivo Formulation Calculator (Clear solution)

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)